Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate
Initiated in March 2019, this Research and Development partnership is focused on the identification of LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix® platform and their potential to act as therapeutic agents against Parkinson’s disease, drawing on Servier and Oncodesign’s complementary expertise in the field of neurodegenerative disease and kinase inhibitors.
Probes of interest in oncology, immunology, central nervous system diseases and rare diseases
Our chemical-based drug discovery approach has generated a set of potent, selective probes with promising drug-like properties that have not yet been developed. Many of these compounds are active at the sub-nanomolar level and demonstrate exceptional initial selectivity on kinases of major interest.
Oncodesign is committed to promoting partnership opportunities in the early stages of drug discovery. We are looking for partners with complementary skills to develop the therapeutic potential of these small cyclic molecules more quickly.